Idera Pharmaceuticals Announces Change of Location for 2020 Annual Meeting of Stockholders
May 01 2020 - 8:00AM
Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq:
IDRA) today provided notice of a change in the location for its
2020 Annual Meeting of Stockholders (the “Annual Meeting”) via the
filing of additional proxy materials with the U.S. Securities and
Exchange Commission.
Due to the public health impact of the coronavirus (COVID-19)
pandemic and related government actions, and to support the health
and well-being of our employees, stockholders, and community, the
location of Idera’s Annual Meeting has been changed and will be
held in a virtual meeting format only. You will not be able to
attend the Annual Meeting in person.
Meeting Date: Tuesday, May 12,
2020Meeting Time: 9:00 a.m. (Eastern
Time)Conference Call Access: (844) 882-7837 (U.S.)
or +1 (574) 990-9824 (international);
Conference Code: 7877966 Webcast Access:
https://edge.media-server.com/mmc/p/8uhpyq28
The Annual Meeting is open to stockholders who owned shares as
of March 24, 2020 (the “Record Date”), proxy holders, and any other
interested party that would like to participate as a guest.
Registered Holders Stockholders are encouraged
to vote and submit proxies in advance of the Annual Meeting by one
of the methods described in the proxy materials for the Annual
Meeting. If you were a stockholder as of the close of business on
the Record Date, you will have the ability to vote during the
Annual Meeting by voice vote after confirming your account number
issued by the Company’s transfer agent, Computershare. You can
obtain your Computershare account number by looking at your most
recent communication from Computershare or by calling
1-800-652-VOTE (8683).
Beneficial HoldersIf you hold your shares
through a broker, bank, or other nominee (that is, in “street
name”), then your broker, bank, or other nominee is the stockholder
of record and such nominee might not be able to vote your shares
unless you provide it with voting instructions. You should instruct
your broker, bank, or other nominee to vote your shares by
following the instructions that your broker, bank, or other nominee
provided when it sent the Company’s proxy materials to you. You may
not vote shares held in street name by returning a proxy card
directly to the Company or via the conference call unless you
provide the Company with a “legal proxy,” which you must obtain
from your broker, bank, or other nominee. If you obtain a legal
proxy and plan to vote at the Annual Meeting via conference call,
then the Company must receive your legal proxy by 5:00 p.m.,
Eastern Time, on May 11, 2020. You will receive an e-mail from the
Company confirming your registration to vote at the Annual Meeting.
Legal proxies may be submitted by mail to: Corporate Secretary,
Idera Pharmaceuticals, Inc., 505 Eagleview Boulevard, Suite 212,
Exton, Pennsylvania 19341; or by e-mail to
legal@iderapharma.com.
If you do not have a valid Computershare account number or legal
proxy, you will still be able to attend the virtual meeting as a
guest; however, you will not have the option to vote your shares
during the virtual meeting or ask questions at the virtual
meeting.
As noted above, all stockholders are encouraged to vote and
submit proxies in advance of the Annual Meeting by one of the
methods described in the proxy materials for the Annual Meeting,
even if you plan to attend the virtual meeting. Please note that
the proxy card included with the proxy materials previously
distributed may continue to be used to vote your shares in
connection with the Annual Meeting. This proxy card will not be
updated to reflect the change in location.
About Idera PharmaceuticalsHarnessing the
approach of the earliest researchers in immunotherapy and the
Company’s vast experience in developing proprietary immunology
platforms, Idera’s lead development program is focused on priming
the immune system to play a more powerful role in fighting cancer,
ultimately increasing the number of people who can benefit from
immunotherapy. Idera also continues to focus on the acquisition,
development, and ultimate commercialization of drug candidates for
both oncology and rare disease indications characterized by small,
well-defined patient populations with serious unmet needs. To learn
more about Idera, visit IderaPharma.com.
Idera Pharmaceuticals Contacts:
Jill Conwell
Investor Relations &
Corporate Communications
Phone (484) 348-1675
JConwell@IderaPharma.comJohn J. Kirby
Chief Financial Officer
Phone (484) 348-1627
JKirby@IderaPharma.com
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Apr 2024 to May 2024
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From May 2023 to May 2024